Purpose
Use Clinical Trial Search to identify relevant studies, evaluate participation details, and follow deterministic inquiry pathways.
Clinical Trial Search
The trial search workbench helps patients, caregivers, and site teams identify synthetic trial opportunities with deterministic filtering controls. The filter model covers condition, phase, recruiting status, radius, age group, and site type so decisions remain transparent and repeatable. Search outputs are anchored to seeded trial records and do not use unbounded generation. Users can refine criteria, preserve state, and open a trial detail with context retained.
Type: CorporateLast reviewed: 2026-02-01Owner: LegalStatus: Approved
Trust Boundary
Trial information is deterministic and transparently separates public study context from workflow-driven operations.
Next Steps
Apply filters, review protocol context, and submit inquiry workflows directly from linked study pages.
Page Focus
This page is a child route in the trials section. Use the dedicated detail content below and related route links for deeper navigation.
TRL-0001 · LYA-200 long-term safety study 1
Status: Recruiting | Phase: Phase 1
Countries: Australia, Brazil
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0002 · LYA-201 long-term safety study 2
Status: Active, not recruiting | Phase: Phase 2
Countries: Germany, France
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0003 · LYA-202 durability study 3
Status: Completed | Phase: Phase 3
Countries: Spain, UK
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0004 · LYA-203 long-term safety study 4
Status: Terminated | Phase: Phase 4
Countries: Spain, France
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0005 · LYA-204 response study 5
Status: Halted | Phase: Phase 1
Countries: Japan, France
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0006 · LYA-205 durability study 6
Status: Recruiting | Phase: Phase 2
Countries: Japan, France
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0007 · LYA-206 long-term safety study 7
Status: Active, not recruiting | Phase: Phase 3
Countries: Spain, France
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0008 · LYA-207 combination study 8
Status: Completed | Phase: Phase 4
Countries: Australia, UK
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0009 · LYA-208 response study 9
Status: Terminated | Phase: Phase 1
Countries: Spain, UK
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0010 · LYA-209 long-term safety study 10
Status: Halted | Phase: Phase 2
Countries: Australia, Brazil
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0011 · LYA-210 durability study 11
Status: Recruiting | Phase: Phase 3
Countries: Germany, Brazil
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0012 · LYA-211 combination study 12
Status: Active, not recruiting | Phase: Phase 4
Countries: Australia, USA
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0013 · LYA-212 response study 13
Status: Completed | Phase: Phase 1
Countries: Canada, UK
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0014 · LYA-213 response study 14
Status: Terminated | Phase: Phase 2
Countries: USA, France
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0015 · LYA-214 long-term safety study 15
Status: Halted | Phase: Phase 3
Countries: Japan, Brazil
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0016 · LYA-215 long-term safety study 16
Status: Recruiting | Phase: Phase 4
Countries: Australia, UK
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0017 · LYA-216 response study 17
Status: Active, not recruiting | Phase: Phase 1
Countries: Australia, France
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0018 · LYA-217 durability study 18
Status: Completed | Phase: Phase 2
Countries: Spain, France
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0019 · LYA-218 combination study 19
Status: Terminated | Phase: Phase 3
Countries: USA, France
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0020 · LYA-219 durability study 20
Status: Halted | Phase: Phase 4
Countries: Canada, Brazil
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0021 · LYA-220 combination study 21
Status: Recruiting | Phase: Phase 1
Countries: Germany, USA
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0022 · LYA-221 durability study 22
Status: Active, not recruiting | Phase: Phase 2
Countries: Japan, UK
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0023 · LYA-222 combination study 23
Status: Completed | Phase: Phase 3
Countries: Spain, Brazil
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0024 · LYA-223 response study 24
Status: Terminated | Phase: Phase 4
Countries: Canada, France
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0025 · LYA-200 response study 25
Status: Halted | Phase: Phase 1
Countries: USA, USA
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0026 · LYA-201 long-term safety study 26
Status: Recruiting | Phase: Phase 2
Countries: Japan, UK
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0027 · LYA-202 long-term safety study 27
Status: Active, not recruiting | Phase: Phase 3
Countries: Canada, France
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0028 · LYA-203 response study 28
Status: Completed | Phase: Phase 4
Countries: Spain, USA
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0029 · LYA-204 durability study 29
Status: Terminated | Phase: Phase 1
Countries: Germany, Brazil
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0030 · LYA-205 response study 30
Status: Halted | Phase: Phase 2
Countries: USA, UK
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0031 · LYA-206 durability study 31
Status: Recruiting | Phase: Phase 3
Countries: Germany, UK
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0032 · LYA-207 response study 32
Status: Active, not recruiting | Phase: Phase 4
Countries: Australia, UK
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0033 · LYA-208 long-term safety study 33
Status: Completed | Phase: Phase 1
Countries: Australia, Brazil
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0034 · LYA-209 response study 34
Status: Terminated | Phase: Phase 2
Countries: Spain, USA
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0035 · LYA-210 response study 35
Status: Halted | Phase: Phase 3
Countries: Spain, France
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0036 · LYA-211 combination study 36
Status: Recruiting | Phase: Phase 4
Countries: Canada, Brazil
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0037 · LYA-212 response study 37
Status: Active, not recruiting | Phase: Phase 1
Countries: Japan, Brazil
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0038 · LYA-213 durability study 38
Status: Completed | Phase: Phase 2
Countries: Japan, France
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0039 · LYA-214 response study 39
Status: Terminated | Phase: Phase 3
Countries: Germany, UK
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0040 · LYA-215 long-term safety study 40
Status: Halted | Phase: Phase 4
Countries: Australia, France
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0041 · LYA-216 long-term safety study 41
Status: Recruiting | Phase: Phase 1
Countries: USA, USA
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0042 · LYA-217 response study 42
Status: Active, not recruiting | Phase: Phase 2
Countries: USA, France
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0043 · LYA-218 durability study 43
Status: Completed | Phase: Phase 3
Countries: Australia, France
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0044 · LYA-219 response study 44
Status: Terminated | Phase: Phase 4
Countries: Spain, Brazil
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0045 · LYA-220 long-term safety study 45
Status: Halted | Phase: Phase 1
Countries: USA, France
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0046 · LYA-221 durability study 46
Status: Recruiting | Phase: Phase 2
Countries: Canada, France
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0047 · LYA-222 long-term safety study 47
Status: Active, not recruiting | Phase: Phase 3
Countries: Germany, France
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0048 · LYA-223 response study 48
Status: Completed | Phase: Phase 4
Countries: Spain, Brazil
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0049 · LYA-200 long-term safety study 49
Status: Terminated | Phase: Phase 1
Countries: Germany, Brazil
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0050 · LYA-201 durability study 50
Status: Halted | Phase: Phase 2
Countries: Spain, UK
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0051 · LYA-202 combination study 51
Status: Recruiting | Phase: Phase 3
Countries: Germany, Brazil
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0052 · LYA-203 combination study 52
Status: Active, not recruiting | Phase: Phase 4
Countries: Spain, UK
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0053 · LYA-204 durability study 53
Status: Completed | Phase: Phase 1
Countries: Japan, Brazil
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0054 · LYA-205 durability study 54
Status: Terminated | Phase: Phase 2
Countries: Spain, USA
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0055 · LYA-206 combination study 55
Status: Halted | Phase: Phase 3
Countries: Canada, Brazil
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0056 · LYA-207 long-term safety study 56
Status: Recruiting | Phase: Phase 4
Countries: Spain, France
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0057 · LYA-208 long-term safety study 57
Status: Active, not recruiting | Phase: Phase 1
Countries: USA, UK
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0058 · LYA-209 long-term safety study 58
Status: Completed | Phase: Phase 2
Countries: Spain, USA
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0059 · LYA-210 response study 59
Status: Terminated | Phase: Phase 3
Countries: Japan, Brazil
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0060 · LYA-211 long-term safety study 60
Status: Halted | Phase: Phase 4
Countries: USA, Brazil
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0061 · LYA-212 combination study 61
Status: Recruiting | Phase: Phase 1
Countries: Japan, France
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0062 · LYA-213 combination study 62
Status: Active, not recruiting | Phase: Phase 2
Countries: Germany, Brazil
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0063 · LYA-214 long-term safety study 63
Status: Completed | Phase: Phase 3
Countries: Germany, USA
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0064 · LYA-215 durability study 64
Status: Terminated | Phase: Phase 4
Countries: Australia, UK
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0065 · LYA-216 response study 65
Status: Halted | Phase: Phase 1
Countries: Japan, USA
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0066 · LYA-217 response study 66
Status: Recruiting | Phase: Phase 2
Countries: Canada, UK
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0067 · LYA-218 durability study 67
Status: Active, not recruiting | Phase: Phase 3
Countries: USA, UK
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0068 · LYA-219 response study 68
Status: Completed | Phase: Phase 4
Countries: Australia, Brazil
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0069 · LYA-220 durability study 69
Status: Terminated | Phase: Phase 1
Countries: Spain, Brazil
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0070 · LYA-221 long-term safety study 70
Status: Halted | Phase: Phase 2
Countries: Australia, USA
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0071 · LYA-222 durability study 71
Status: Recruiting | Phase: Phase 3
Countries: Australia, Brazil
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0072 · LYA-223 long-term safety study 72
Status: Active, not recruiting | Phase: Phase 4
Countries: Germany, Brazil
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0073 · LYA-200 long-term safety study 73
Status: Completed | Phase: Phase 1
Countries: Canada, France
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0074 · LYA-201 long-term safety study 74
Status: Terminated | Phase: Phase 2
Countries: USA, UK
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0075 · LYA-202 long-term safety study 75
Status: Halted | Phase: Phase 3
Countries: Australia, USA
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0076 · LYA-203 combination study 76
Status: Recruiting | Phase: Phase 4
Countries: Canada, Brazil
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0077 · LYA-204 long-term safety study 77
Status: Active, not recruiting | Phase: Phase 1
Countries: Japan, USA
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0078 · LYA-205 response study 78
Status: Completed | Phase: Phase 2
Countries: Canada, USA
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0079 · LYA-206 durability study 79
Status: Terminated | Phase: Phase 3
Countries: Australia, France
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial DetailsTRL-0080 · LYA-207 durability study 80
Status: Halted | Phase: Phase 4
Countries: Germany, UK
Eligibility snapshot: biomarker-aligned adults, protocol-defined baseline assessments, and controlled follow-up windows.
Trial Details